Please join us for the 2019 Conference on Retroviruses and Opportunistic Infections (CROI), the world's foremost gathering of HIV/AIDS research scientists, clinicians, educators, and policy makers, to be held March 4, 2019, through March 7, 2019, in Seattle, Washington, USA. Information about online registration along with a wealth of material about the Conference, its events, travel, and local accommodations can be found on the CROI website. This invitation does not imply a guarantee of acceptance or any financial assistance to ensure your presence. All invitees must plan to attend at their own expense. We advise you to contact the appropriate government authorities and the Embassy or Consulate in your country in order to facilitate all travel and visa requirements.
More than 4000 attendees are expected at this year's CROI, a model of global collaborative science and the premier international venue for developing the most effective clinical practices from cutting-edge research.
Rigorous and groundbreaking work from molecular studies to epidemiologic research will engage presenters and attendees in fruitful presentations, critiques, and discussions throughout the 3-day Conference. From the opening plenary sessions through the oral abstracts, poster presentations, workshops, and informal gatherings with leading scientists, attendees will be immersed in an educational experience unrivaled today in comprehensiveness and quality.
Registration for authors of accepted abstracts opens in Mid-November 2018, and for others on December 1, 2018. Registration and housing closes to all applicants on February 7, 2019, unless the registration limit of 4000 had already been reached. We encourage you to submit your registration application as soon as registration opens. To access the registration form directly, visit: http://www.croiconference.org/registration.
We look forward to seeing you in Boston.
Donna M. Jacobsen
Executive Director/President, IAS–USA
Executive Manager, CROI
On behalf of Susan P. Buchbinder, MD, Chair, University of California San Francisco; Judith S. Currier, MD, MSc, Vice Chair, David Geffen School of Medicine; Richard A. Koup, MD, Vice Chair, Vaccine Research Center, NIAIDS, NIH